Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma

• Published in: The Prostate Vol. 79; no. 6; pp. 592 - 603
• Main Authors: Padda, Ranjit S., Deng, Florence K., Brett, Sabine I., Biggs, Colleen N., Durfee, Paul N., Brinker, Charles J., Williams, Karla C., Leong, Hon S.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2019
• Subjects: benign prostatic hyperplasia; CD63; CD63 antigen; CD81 antigen; CD9; CD9 antigen; Cell membranes; Exocytosis; Exosomes; Extracellular vesicles; Flow cytometry; Hyperplasia; Microparticles; nanoscale flow cytometry; Plasma; Prostate cancer; PSMA; nanoscale flow cytometry; CD63; PSMA; prostate cancer; extracellular vesicles; exosomes; CD9; benign prostatic hyperplasia
• ISSN: 0270-4137; 1097-0045
• DOI: 10.1002/pros.23764

Objective To determine if prostate‐derived extracellular vesicles (EVs) present in patient plasma samples are of exocytotic origin (exosomes) or released by the cell membrane (microparticles/microvesicles). Both malignant and normal prostate cells release two types of EVs into the circulation, exosomes, and microparticles/microvesicles which differ in size, origin, and mode of release. Determining what proportion of prostate‐derived EVs are of exosomal versus microparticle/microvesicle EV subtype is of potential diagnostic significance. Materials and Methods Multi‐parametric analytical platforms such as nanoscale flow cytometry (nFC) were used to analyze prostate derived extracellular vesicles. Plasmas from prostate cancer (PCa) patient plasmas representing benign prostatic hyperplasia (BPH), low grade prostate cancer (Gleason Score 3 + 3) and high grade prostate cancer (Gleason Score ≥4 + 4) were analyzed for various exosome markers (CD9, CD63, CD81) and a prostate specific tissue marker (prostate specific membrane antigen/PSMA). Results By using nanoscale flow cytometry, we determine that prostate derived EVs are primarily of cell membrane origin, microparticles/microvesicles, and not all PSMA expressing EVs co‐express exosomal markers such as CD9, CD63, and CD81. CD9 was the most abundant exosomal marker on prostate derived EVs (12‐19%). There was no trend observed in terms of more PSMA + CD9 or PSMA + CD63 co‐expressing EVs versus increasing grade of prostate cancer. Conclusion The majority of prostate derived EVs present in plasmas are from the cell membrane as evidenced by their size and most importantly, lack of co‐expression of exosomal markers such as CD9/CD63/CD81. In fact, CD81 was not present on any prostate derived EVs in patient plasmas whereas CD9 was present on a minority of prostate derived EVs. The addition of an exosomal marker for detection of prostate‐derived EVs does not provide greater clarity in distinguishing EVs released by the prostate.